site sponsored by
-
FDA wants drug companies to enforce REMS with physicians. Is this realistic ?
28 July 2010
REMS .
Posted in: DTC Comments
-
How DO You Pronounce "Boehringer Ingelheim"?
27 July 2010
Yesterday, while at ExL's 6th Annual Public Relations & Communications Summit , I discovered that I was NOT the only person who had difficulty pronouncing "Boehringer Ingelheim," the name of a well-known, but difficult to pronounce German pharmaceutical company. At a roundtable discussion (see here ), Kate O'Connor , Executive Director, Public Relations at Boehringer Ingelheim, corrected someone else who mispronounced her company's name.
Posted in: Web Marketing Comments
-
Using Social Media in a Crisis: Distribute a Product Safety Widget Is One Idea
27 July 2010
The "Social Media During a Crisis" roundtable discussion lead by Deborah Sittig ( @GreenRoomMedia ), Partner at Green Room Public Relations, was one of the most interesting events for me at ExL Pharma's 6th Annual Public Relations & Communications Summit . The question posed for discussion was "How can digital communications be utilized to best support patient safety during a crisis situation." Also of importance was how to best protect the company's image during a crisis
Posted in: Traditional Strategies Comments
-
A little drug problem: perception
27 July 2010
For every million people who take a statin for high cholesterol, there are 50,000 fewer angioplasties, surgeries, heart-attacks, strokes, and CV deaths, studies have shown. In the past 15 years, drugs have transformed AIDS from a death sentence into a managed disease. A life saved or transformed because of the drug industry
Posted in: DTC Comments
-
Genzyme Telling Sanofi-Aventis to Buzz Off?
27 July 2010
That's what Bloomberg is reporting . Meanwhile, the Wall Street Journal reported that GlaxoSmithKline has expressed interest in the recent past, and that J&J might get involved as well. If a deal goes through, no matter who ends up making it, it'll be a lot more expensive than it looked like being.
Posted in: In the Pipeline Comments
-
How Sleazy It Can Get
27 July 2010
I've written several times about pharma/biotech companies whose stock promotion strategies seem suspect. But there are always more layers below. A reader sends along this headache-inducing promotion for a company called A5 Laboratories (no link from me to their website).
Posted in: In the Pipeline Comments
-
FDA Advances in Social Media - What’s it Mean for Industry?
27 July 2010
Greetings from the 6 th Annual PR & Communications ExL Pharma Summit being held in the headquarters of Pfizer in New York, yesterday and today.
Posted in: Regulatory Comments
-
ePharma Summit: Maximizing Your Returns Online
27 July 2010
ePharma Summit 2010 took place this past February in Philadelphia. If you were unable to make it, we will now be presenting a weekly video series featuring all of the sessions from our event.
Posted in: Web Marketing Comments
-
Media Blackout Imposed by Media People!
27 July 2010
I spent yesterday at Pfizer headquarters in NYC attending and speaking at ExL Pharma's 6th Annual Public Relations & Communications Summit . I met some of my Twitter pals there including Ray Kerins ( @RayKerins ), Steve Woodruff ( @swoodruff ), Mario Nacinovich ( @nacinovich ), and Zoe Elliott Dunn ( @zelliott ), among others.
Posted in: Traditional Strategies Comments
-
Alzheimer’s and Amyloid, Again
27 July 2010
I wanted to mention this good article in the New York Times on the amyloid hypothesis and Alzheimer's.
Posted in: In the Pipeline Comments
Ask Our Experts
Heather R. Powell
Regulatory
Dawn Obermoeller
Social Media
Jonathan Richman
Non-Personal Promotion
Optimize RX
Internet Marketing & Analytics
Share Your Knowledge
We are always seeking seasoned pharmaceutical marketing professonals as contributors. If you have a strong background in pharmacetical marketing, and are interested in sharing your skills and knowledge with our community, or syndicating your existing blog posts, please click here.
- Popular
- Latest
- Comments
- Tags
- Subscribe
- Design: Flash-banner-eyebrow nightmare
- Even After Patent Cliff, Pfizer Is Undervalued
- Sanofi Board Said to Support Genzyme Bid of Up to $18.7 Billion
- FTC: âTide May Be Turningâ On Pay-To-Delay Deals
- Celgene Beats and Raises Guidance
- Who is Killing the Pharmaceutical Sales Position?
- Snafi – HCP print ad in the UAE
- Hospira plans big study for new Epogen biosimilar
- New from OSI / Astellas
- Athersys buoyed by upbeat PhI stem cell data
- Optimize RX: yep - recvd - thanks - how much daily u.v.'s r u g...
- JMB: This is another bashing article from an author who...
- Martin: It's just silly of you to obsess over the possibil...
- Gregg Feris: Jon, Thanks for the in depth reply. I like the ...
- Doc: Why should Exxon have to pay this fine for somethi...
Stay up to date
- Subscribe to the RSS Feed
